ARIAD Pharmaceuticals
ARIAD is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Launch date
Employees
Market cap
-
Enterprise valuation
$5.2b (Public information from Jan 2017)
Cambridge Massachusetts (HQ)
Financials
Estimates*
EUR | 2015 |
---|---|
R&D budget | 152m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$46.0m | Early VC | ||
N/A | N/A | IPO | |
N/A | $8.0m | Post IPO Equity | |
N/A | $6.1m | Post IPO Equity | |
$10.0m | Post IPO Equity | ||
N/A | $41.0m | Post IPO Equity | |
N/A | $9.4m | Post IPO Equity | |
$14.0m | Post IPO Equity | ||
$5.2b Valuation: $5.2b | Acquisition | ||
Total Funding | $46.0m |
Recent News about ARIAD Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ARIAD Pharmaceuticals
EditACQUISITION by Concentra Biosciences Dec 2023